Luhan Pharmachem Co., Ltd.

Luhan pharmachem Co., Ltd. supplies Clevidipine Butyrate bulk active pharmaceutical ingredient (API) to the pharmaceutical industry. Our Clevidipine Butyrate is manufactured by cGMP compliant facility. Welcome to contact us for further details including current DMF status for the product and up to date regulatory status of the manufacturing facility. We look forward to assisting you with your research and development projects.

What is Clevidipine butyrate?

Clevidipine is a dihydropyridine calcium channel blocker indicated for the reduction of blood pressure when oral therapy is not feasible or not desirable. It was approved by the United States Food and Drug Administration on August 1, 2008.

Clevidipine is a dihydropyridine calcium channel blocker. Chemically, clevidipine, is butyroxymethyl methyl 4-(2´, 3´-dichlorophenyl)-1, 4-dihydro-2, 6-dimethyl-3, 5-pyridinedicarboxylate. It is a racemic mixture with a molecular weight of 456.3 g/mol. Each enantiomer has equipotent antihypertensive activity.

Clevidipine butyrate Drug Interactions

Clevidipine and its major dihydropyridine metabolite do not have the potential for blocking or inducing any CYP enzyme.

Precautions before using Clevidipine butyrate

Need for Aseptic Technique

Use aseptic technique and discard any unused product within 12 hours of stopper puncture.

Hypotension and Reflex Tachycardia

Clevidipine may produce systemic hypotension and reflex tachycardia. If either occurs, look decrease the dose of Clevidipine. There is limited experience with short-duration therapy with beta-blockers as a treatment for Clevidipine-induced tachycardia. Beta-blocker use for this purpose is not recommended.

Negative Inotropy

Dihydropyridine calcium channel blockers can produce negative inotropic effects and exacerbate heart failure. Monitor heart failure patients carefully.

Beta-Blocker Withdrawal

Clevidipine is not a beta-blocker, and does not reduce heart rate, and gives no protection against the effects of abrupt beta-blocker withdrawal. Beta-blockers should be withdrawn only after a gradual reduction in dose.

Rebound Hypertension

Patients who receive prolonged Clevidipine infusions and are not transitioned to other antihypertensive therapies should be monitored for the possibility of rebound hypertension for at least 8 hours after the infusion is stopped.

Pheochromocytoma

There is no information to guide use of Clevidipine in treating hypertension associated with pheochromocytoma.

Clevidipine butyrate Side effects

Most common adverse reactions (>2%) are headache, nausea, and vomiting.

Clevidipine butyrate Storage

Clevidipine is photosensitive and storage in cartons protects against photodegradation. Protection from light during administration is not required.

Store vials refrigerated at 2-8°C (36-46°F). Do not freeze. Vials in cartons may be transferred to 25°C (77°F, USP controlled room temperature) for a period not to exceed 2 months. Upon transfer to room temperature, mark vials in cartons “This product was removed from the refrigerator on _/_/_ date. It must be used or discarded 2 months after this date or the labeled expiration date (whichever date comes first).” Do not return to refrigerated storage after beginning room temperature storage.

Disclaimer:

Information on this page is provided for general information purposes. You should not make a clinical treatment decision based on information contained in this page without consulting other references including the package insert of the drug, textbooks and where relevant, expert opinion. We cannot be held responsible for any errors you make in administering drugs mentioned on this page, nor for use of any erroneous information contained on this page.